Impact of cancer diagnosis on life expectancy by area-level socioeconomic groups in New South Wales, Australia: a population-based study.

Cancer diagnosis area-level socioeconomic status flexible parametric model life expectancy loss of life expectancy

Journal

Cancer biology & medicine
ISSN: 2095-3941
Titre abrégé: Cancer Biol Med
Pays: China
ID NLM: 101588850

Informations de publication

Date de publication:
22 Jul 2024
Historique:
medline: 22 7 2024
pubmed: 22 7 2024
entrez: 22 7 2024
Statut: aheadofprint

Résumé

Improvement in cancer survival over recent decades has not been accompanied by a narrowing of socioeconomic disparities. This study aimed to quantify the loss of life expectancy (LOLE) resulting from a cancer diagnosis and examine disparities in LOLE based on area-level socioeconomic status (SES). Data were collected for all people between 50 and 89 years of age who were diagnosed with cancer, registered in the NSW Cancer Registry between 2001 and 2019, and underwent mortality follow-up evaluations until December 2020. Flexible parametric survival models were fitted to estimate the LOLE by gender and area-level SES for 12 common cancers. Of 422,680 people with cancer, 24% and 18% lived in the most and least disadvantaged areas, respectively. Patients from the most disadvantaged areas had a significantly greater average LOLE than patients from the least disadvantaged areas for cancers with high survival rates, including prostate [2.9 years (95% CI: 2.5-3.2 years) Patients from the most disadvantaged areas had the highest LOLE with SES-based differences greatest for patients diagnosed with cancer at an early stage or cancers with higher survival rates, suggesting the need to prioritise early detection and reduce treatment-related barriers and survivorship challenges to improve life expectancy.

Identifiants

pubmed: 39037292
pii: j.issn.2095-3941.2024.0166
doi: 10.20892/j.issn.2095-3941.2024.0166
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Health and Research Council of Australia Leadership Investigator
ID : NHMRC; APP1194679

Informations de copyright

Copyright: © 2024, The Authors.

Déclaration de conflit d'intérêts

No potential conflicts of interest are disclosed.

Auteurs

Md Mijanur Rahman (MM)

The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 1340, Australia.

Michael David (M)

The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 1340, Australia.
School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4222, Australia.

David Goldsbury (D)

The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 1340, Australia.

Karen Canfell (K)

The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 1340, Australia.

Kou Kou (K)

Cancer Council Queensland, Brisbane, QLD 4006, Australia.

Paramita Dasgupta (P)

Cancer Council Queensland, Brisbane, QLD 4006, Australia.

Peter Baade (P)

Cancer Council Queensland, Brisbane, QLD 4006, Australia.

Xue Qin Yu (XQ)

The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW 1340, Australia.

Classifications MeSH